Expert Insights for Hematology/Oncology Pharmacists on Later-Generation TKIs as Frontline Therapy in Chronic-Phase CML

Hematologists and oncologists will be able to recommend personalized treatment strategies that include later-generation tyrosine kinase inhibitors as frontline therapy for patients with chronic-phase CML after reviewing recent clinical evidence on their use to improve patient outcomes and increase the likelihood of treatment-free remission through an on-demand webcast, ClinicalThought commentary, and accompanying downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by ProCE LLC, in partnership with Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner